相关论文: Geometric Modeling of Hippocampal Tau Deposition: …
Background: Alzheimer's Disease (AD) is the most common type of age-related dementia, affecting 6.2 million people aged 65 or older according to CDC data. It is commonly agreed that discovering an effective AD diagnosis biomarker could have…
Background: Beta-amyloid (A$\beta$) plaques and tau protein tangles in the brain are the defining 'A' and 'T' hallmarks of Alzheimer's disease (AD), and together with structural atrophy detectable on brain magnetic resonance imaging (MRI)…
Biomarker-assisted diagnosis and intervention in Alzheimer's disease (AD) may be the key to prevention breakthroughs. One of the hallmarks of AD is the accumulation of tau plaques in the human brain. However, current methods to detect tau…
Early and accessible detection of Alzheimer's disease (AD) remains a critical clinical challenge, and cube-copying tasks offer a simple yet informative assessment of visuospatial function. This work proposes a multimodal framework that…
Accurate quantification of tau pathology via tau positron emission tomography (PET) scan is crucial for diagnosing and monitoring Alzheimer's disease (AD). However, the high cost and limited availability of tau PET restrict its widespread…
The emergence of tau PET imaging over the last decade has enabled Alzheimer's disease (AD) researchers to examine tau pathology in vivo and more effectively characterize the disease trajectories of AD. Current tau PET analysis methods,…
Aggregates of misfolded tau proteins (or just 'tau' for brevity) play a crucial role in the progression of Alzheimer's disease (AD) as they correlate with cell death and accelerated tissue atrophy. Longitudinal positron emission tomography…
Alzheimer's disease is the most common neurodegenerative disorder. Its pathological development is connected with the misfolding and accumulation of two toxic proteins: amyloid-beta and tau proteins. Mathematical models provide a valuable…
Confirming Alzheimer's disease (AD) typically relies on positron emission tomography (PET), which remains costly and invasive, motivating the use of structural MRI-based prescreening. Deep learning on non-Euclidean manifolds, particularly…
One of the hallmarks of Alzheimer's disease (AD) is the accumulation and spread of toxic aggregates of tau protein. The progression of AD tau pathology is thought to be highly stereotyped, which is in part due to the fact that tau can…
In this study, we proposed and evaluated a graph-based framework to assess variations in Alzheimer's disease (AD) neuropathologies, focusing on classic (cAD) and rapid (rpAD) progression forms. Histopathological images are converted into…
Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by the accumulation of amyloid-beta (A$\beta$) and phosphorylated tau (p-tau) proteins, leading to cognitive decline measured by the Alzheimer's Disease…
Alzheimer's disease (AD) is a complex neurodegenerative condition that manifests at multiple levels and involves a spectrum of abnormalities ranging from the cellular to cognitive. Here, we investigate the impact of AD-related tau-pathology…
Alzheimer's Disease (AD) is a progressive neurodegenerative condition that adversely affects cognitive abilities. Language-related changes can be automatically identified through the analysis of outputs from linguistic assessment tasks,…
Tau positron emission tomography (tau-PET) is an important in vivo biomarker of Alzheimer's disease, but its cost, limited availability, and acquisition burden restrict broad clinical use. This work proposes an interpretable multimodal…
Imaging-based early diagnosis of Alzheimer Disease (AD) has become an effective approach, especially by using nuclear medicine imaging techniques such as Positron Emission Topography (PET). In various literature it has been found that PET…
We propose a method that uses a two-species ordinary differential equation (ODE) model to characterize misfolded tau (or simply tau) protein spreading in Alzheimer's disease (AD) and calibrates it from clinical data. The unknown model…
Alzheimer's disease (AD) and mild cognitive impairment (MCI) are associated with progressive gray matter loss, particularly in medial temporal structures. In this study, CAT12/SPM12 voxel-based morphometry was applied to baseline…
Alzheimer's disease (AD) confirmation often relies on positron emission tomography (PET) or cerebrospinal fluid (CSF) analysis, which are costly and invasive. Consequently, structural MRI biomarkers such as cortical thickness (CT) are…
Alzheimer's disease is a progressive form of dementia that results in problems with memory, thinking, and behavior. It often starts with abnormal aggregation and deposition of beta amyloid and tau, followed by neuronal damage such as…